-transparent.png){kind=logo}
Cyclosporin blood trough levels were measured with four different immunoassays and high-performance liquid chromatography in 12 patients receiving low-dose steroids and CsA after kidney transplantation. These patients represent a selection with an uncomplicated posttransplant course and received no drugs with a known influence on CsA pharmacokinetics. The use of specific antibodies against the parent drug yielded levels comparable to those detected by HPLC. CsA levels measured with nonspecific antibodies exceeded those measured with specific ones by a factor of two to three. All immunoassay-detected CsA levels correlated significantly with the HPLC-determined CsA levels. In addition, blood levels of the CsA metabolites 1, 17, 18, and 21 were determined by HPLC. In one additional patient, who was under tuberculostatic treatment and had a transitory deterioration of liver function, levels of nonspecific-antibody-determined CsA rose, as confirmed by rising levels of metabolite 17, while those of the parent drug fell. We conclude that routine drug monitoring should include at least one immunoassay with a specific antibody detecting the unchanged CsA, and a supplementary immunoassay with a nonspecific antibody detecting a composition of cross-reacting metabolites plus the unchanged substance. If available, HPLC should be used to confirm levels of CsA and its metabolites in patients with suspected alteration of their CsA metabolism.
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
November 2000,
Clinical chemistry and laboratory medicine,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
September 2017,
Therapeutic advances in gastroenterology,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
January 2003,
Clinical laboratory,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
January 1989,
Clinical chemistry,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
April 2020,
Clinical biochemistry,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
January 2022,
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
October 1998,
Clinical chemistry,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
June 1987,
Clinics in laboratory medicine,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
June 2023,
International journal of molecular sciences,
U Kunzendorf, and
J Brockmöller, and
F Jochimsen, and
F Keller, and
I Roots, and
G Walz, and
G Offermann
December 1995,
Therapeutic drug monitoring,
